{"id":4284,"date":"2025-03-31T18:12:03","date_gmt":"2025-03-31T18:12:03","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/paroxetine-txt\/"},"modified":"2025-03-31T18:12:03","modified_gmt":"2025-03-31T18:12:03","slug":"paroxetine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/paroxetine-txt\/","title":{"rendered":"Paroxetine.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntidepressant:Panic disorders Obsessive compulsive disorder Social anxiety Post traumatic stress disorder

DOSE IN NORMAL RENAL FUNCTION <\/H3>10\u201360 mg daily depending on indication

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :329.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :95<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <2<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :13<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :24\/30

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 Dose as in normal renal function10\u201330 20 mg daily and titrate slowly
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 20 mg daily and titrate slowly

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as for GFR=10\u201330 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: increased risk of bleeding with aspirin and NSAIDs; increased risk of CNS toxicity with tramadol\n
  • Anti-arrhythmics: possibly inhibits propafenone metabolism (increased risk of toxicity)\n
  • Anticoagulants: effect of coumarins possibly enhanced\n
  • Antidepressants: avoid concomitant use with MAOIs and moclobemide (increased risk of toxicity); avoid concomitant use with St John\u2019s wort; possibly enhanced serotonergic effects with duloxetine; can increase tricyclics antidepressant concentration; increased agitation and nausea with tryptophan\n
  • Anti-epileptics: antagonism (lowered convulsive threshold); concentration reduced by carbamazepine, phenytoin and primidone\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: concentration of clozapine, sertindole and possibly risperidone increased; metabolism of perphenazine inhibited, reduce dose of perphenazine; possibly inhibit aripiprazole metabolism, reduce aripiprazole dose\n
  • Antivirals: concentration increased by ritonavir\n
  • Dopaminergics: use entacapone with caution; increased risk of hypertension and CNS excitation with selegiline \u2013 avoid concomitant use; increased risk of CNS toxicity with rasagiline \u2013 avoid concomitant use5HT 1 agonist: risk of CNS toxicity increased by sumatriptan \u2013 avoid concomitant use; possibly increased risk of serotonergic effects with frovatriptan\n
  • Lithium: increased risk of CNS effects \u2013 monitor levels\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antidepressant:Panic disorders Obsessive compulsive disorder Social anxiety Post<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4284","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4284"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4284\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}